A Phase 2A Open-label Trial to Assess the Safety of ZIMURA™ (Anti-C5) Administered in Combination With LUCENTIS® 0.5 mg in Treatment Naive Subjects With Neovascular Age Related Macular Degeneration

Trial Profile

A Phase 2A Open-label Trial to Assess the Safety of ZIMURA™ (Anti-C5) Administered in Combination With LUCENTIS® 0.5 mg in Treatment Naive Subjects With Neovascular Age Related Macular Degeneration

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2017

At a glance

  • Drugs Avacincaptad pegol (Primary) ; Ranibizumab (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors OphthoTech Corporation
  • Most Recent Events

    • 08 Nov 2017 According to an OphthoTech Corporation media release, based on the anticipated enrollment rate, the Company expects initial top-line data from this trial to be available by the end of 2018.
    • 19 Sep 2017 Status changed from planning to recruiting, according to an OphthoTech Corporation media release.
    • 31 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top